Oncolytics Biotech is trading 5% lower at $0.68, with the decline appearing to reflect stock-specific selling; no confirmed company-specific catalyst has been identified for September 23, 2026. - The latest reported announcement was positive preclinical data released September 10 involving pelareorep and a pan-RAS inhibitor; it does not explain today’s decline. - The broader biotechnology sector is rising, so sector strength does not explain the stock’s weakness. - Limited news coverage is currently available.